ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Selenium-Doped Nanoheterojunctions for Highly Efficient Cancer Radiosensitization.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Landscape and evolutionary trends of nanotechnology in cancer radiosensitization.Discover nano · 2026Review
- Selenium-Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Green synthesis of selenium nanoparticles using Bacillus sp. strain STG-83: optimization, characterization, and prospects for cancer radiosensitization.Scientific reports · 2026Article
- [Selenocystine inhibits colon cancer cell growth by promoting reactive oxygen species generation to trigger oxidative damage].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Hybrid biomaterials-based radiosensitizers: Preparations and their applications in enhancing tumor radiotherapy.Materials today. Bio · 2025Article
- Novel intravenous formulation for radiosensitization in osteosarcoma treatment.Materials today. Bio · 2025Article
- Radio-Activated Selenium-Doped Janus Ag/AgAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Selenium nanoparticles activate selenoproteins to mitigate septic lung injury through miR-20b-mediated RORγt/STAT3/Th17 axis inhibition and enhanced mitochondrial transfer in BMSCs.Journal of nanobiotechnology · 2025Article
- Bioeliminable Pt@BiTheranostics · 2025Article
- Metabolizable alloy clusters assemble nanoinhibitor for enhanced radiotherapy of tumor by hypoxia alleviation and intracellular PD-L1 restraint.Journal of nanobiotechnology · 2024Article
- Selenium Attenuates Radiation Colitis by Regulating cGAS-STING Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Selenium-Doped Nanoheterojunctions for Highly Efficient Cancer Radiosensitization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Exploring efficient and low-toxicity radiosensitizers to break through the bottleneck of radiation tolerance, immunosuppression and poor prognosis remains one of the critical developmental challenges in radiotherapy. Nanoheterojunctions, due to their unique physicochemical properties, have demonstrated excellent radiosensitization effects in radiation energy deposition and in lifting tumor radiotherapy inhibition. Herein, they doped selenium (Se) into prussian blue (PB) to construct a nano-heterojunction (Se@PB), which could promote the increase of Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.